Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients
Open Access
- 15 October 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (20) , 12361
Abstract
The measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molecule Array (Simoa) and the Ella microfluid platform, to measure longitudinal sNfL levels of 42 highly active multiple sclerosis patients treated with alemtuzumab over a period of 36 months. In order to assess the methods agreement, Bland–Altman plots and Passing–Bablok regression were analyzed. Here, we show that despite the fact that Ella measures around 24% higher values than Simoa, both are equally suitable for longitudinal sNfL monitoring.Keywords
This publication has 20 references indexed in Scilit:
- Profiling individual clinical responses by high-frequency serum neurofilament assessment in MSNeurology Neuroimmunology & Neuroinflammation, 2019
- Neurofilament light chain as a biomarker in neurological disordersJournal of Neurology, Neurosurgery & Psychiatry, 2019
- Blood neurofilament light chain as a biomarker of MS disease activity and treatment responseNeurology, 2019
- Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2018
- Neurofilaments as biomarkers in neurological disordersNature Reviews Neurology, 2018
- Neurofilaments and 10-year follow-up in multiple sclerosisMultiple Sclerosis Journal, 2018
- Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimodMultiple Sclerosis Journal, 2017
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnnals of Neurology, 2017
- Serum neurofilament is associated with progression of brain atrophy and disability in early MSNeurology, 2017
- Method comparison in the clinical laboratoryVeterinary Clinical Pathology, 2006